|
| |
| Drug Development |
|
ReceptoPharm is developing proprietary
therapeutic protein products for the treatment of neurological,
viral and and autoimmune disorders. |
| »
Learn More |
|
|
| |
| CRO Services |
ReceptoPharm offers a full range of contract
research services catering to small and start-up biotech companies. |
| » Learn More |
|
|
|
ReceptoPharm's research and development
pipeline consists of several novel therapies
in various stages of development to prevent
and/or treat Multiple Sclerosis (MS), Human
Immunodeficiency Virus (HIV), Adrenomyeloneuropathy
(AMN), Herpes, Rheumatoid Arthritis (RA)
and Pain.
| |
Planning |
|
| |
In Progress |
|
| |
Completed |
|
|
|
Abbreviations
Preclinical (PC), Phase 1 (P-I), Phase 2
(P-II), Phase 3 (P-III)
| |
Indication |
PC |
P-I |
P-II |
P-III |
| |
|
|
|
|
|
| |
|
|
|
|
|
|
| |
Indication |
Regulatory Status |
| |
Chronic Pain (OTC) |
Marketing |
|
| |
 |
|
| Cobroxin is the first over-the-counter pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis. For more information, visit http://www.Cobroxin.com. |
|
|
| |
Indication |
Regulatory Status |
| |
Chronic Pain (OTC) |
Undergoing International Registrations |
| |
Chronic Pain (Rx) |
Undergoing International Registrations |
|
| |
 |
|
| Nyloxin is a treatment for moderate to severe chronic pain. The over-the-counter formulation, Nyloxin OTC, is aimed at treating moderate to severe (Stage 2) chronic pain. The prescription strength formulation, Nyloxin Rx, is aimed at treating severe (Stage 3) chronic pain and is intended for distribution worldwide, including in the United States. For more information, visit http://www.Nyloxin.com. |
|
|
|
|
|
| |
| E-Alerts
|
| Signup to receive news and announcements
from ReceptoPharm and Nutra Pharma: |
|
|
|
|
|
|
|
